Ivermectin treatment in humans for reducing malaria transmission

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 9, 2018, Pages

  de Souza, Dziedzom Komi ^a   Larbi, Irene ^a   Boakye, Daniel A ^a   Okebe, Joseph ^b  

^a University of Ghana   (Ghana)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN;

DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; MALARIA; MALARIA CONTROL; MOSQUITO; NONHUMAN; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VIRUS TRANSMISSION;

EID: 85052640605     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD013117     Document Type: Review

References (60)

1. Alout H, Krajacich BJ, Meyers JI, Grubaugh ND, Brackney DE, Kobylinski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malaria Journal 2014;13:417.
2. Beier JC, Mueller GC, GU W, Arheart KL, Schlein Y. Attractive toxic sugar bait (ATSB) methods decimate populations of Anopheles malaria vectors in arid environments regardless of the local availability of favoured sugar-source blossoms. Malaria Journal 2012;11:31.
3. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015;526(7572):207-11.
4. Blanford JI, Blanford S, Crane RG, Mann ME, Paaijmans KP, Schreiber KV, et al. Implications of temperature variation for malaria parasite development across Africa. Scientific Reports 2013;3:1300.
5. Boussinesq M, Gardon M, Kamgno J, Pion SDS, Gardon-Wendel N, Chippaux J-P. Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon. Annals of Tropical Medicine and Parasitology 2001;95(5):495-507.
6. Briët OJ, Chitnis N. Effects of changing mosquito host searching behaviour on the cost effectiveness of a mass distribution of long-lasting, insecticidal nets: a modelling study. Malaria Journal 2013;12:215.
7. Brown KR, Ricci FM, Ottesen EA. Ivermectin: effectiveness in lymphatic filariasis. Parasitology 2000;121(Suppl):S133-46.
8. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrobial Agents and Chemotherapy 1979;15(3):361-7.
9. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. Journal of Infectious Diseases 2010;202(1):113-6.
10. Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, et al. Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda. Malaria Journal 2015;14:243.
11. Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H. The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. eLife 2016;5:pii: e16090. [PUBMED: 27547988]
12. Clements AN. The Biology of Mosquitoes. Development, Nutrition, and Reproduction. London: Chapman & Hall, 1992:509.
13. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 2013;382(9895):900-11.
14. Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Tropica 2011;120(Suppl 1):S100-8.
15. Derua YA, Kisinza WN, Simonsen PE. Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasites & Vectors 2015;8:130.
16. Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. European Journal of Clinical Pharmacology 1988;35(6):681-4.
17. Ejere HOD, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD002219.pub2]
18. Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Tropical Medicine and Parasitology 1991;42(2):79-81.
19. Farrar J, Hotez P, Junghanss T, Kang G, Lalloo D, White NJ. Manson's Tropical Diseases. 23rd Edition. UK: Elsevier Health Sciences, 2013.
20. Foley DH, Bryan JH, Lawrence GW. The potential of ivermectin to control the malaria vector Anopheles farauti. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000;94(6):625-8.
21. Gardon J, Gardon-Wendel N, Ngangue D, Kamgno J, Chippaux J-P, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa. Lancet 1997;350(9070):18-20.
22. Golan DT, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 3rd Edition. Philadelphia: LLW, 2011.
23. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans - a mini-review. American Association of Pharmaceutical Scientists Journal 2008;10(1):42-6.
24. Govella NJ, Chaki PP, Killeen GF. Entomological surveillance of behavioural resilience and resistance in residual malaria vector populations. Malaria Journal 2013;12:124.
25. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 30 May 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
26. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendation. BMJ 2008;336:924.
27. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infectious Diseases 2004;4(6):327-36. [PUBMED: 15172341]
28. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
29. Ikeda T. Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 2003;122(6):527-38. [PUBMED: 14639007]
30. Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004;98(8):496-504.
31. Killeen GF. Characterizing, controlling and eliminating residual malaria transmission. Malaria Journal 2014;13:330.
32. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. American Journal of Tropical Medicine and Hygiene 2011;85(1):3-5.
33. Kumaraswami V, Ottesen EA, Vijayasekaran V, Devi U, Swaminathan M, Aziz MA, et al. Ivermectin for the treatment of Wuchereria bancrofti filariasis. Efficacy and adverse reactions. JAMA 1988;259(21):3150-3.
34. Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
35. Makunde WH, Kamugisha LM, Massaga JJ, Makunde RW, Savael ZX, Akida J, et al. Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis. Filaria Journal 2003;2(1):15.
36. Merck, Co. Stromectol. FDA-approved package insert. www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf (accessed 30 May 2018).
37. Meyers JI, Gray M, Kuklinski W, Johnson LB, Snow CD, Black WC IV, et al. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. Journal of Experimental Biology 2015;218(Pt 10):1478-86.
38. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends in Parasitology 2003;19(11):516-22.
39. Mueller GC, Beier JC, Traore SF, Toure MB, Traore MM, Bah S, et al. Successful field trial of attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the Anopheles gambiae complex in Mali, West Africa. Malaria Journal 2010;9:210.
40. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. American Journal of Tropical Medicine and Hygiene 2015;93(1):125-34.
41. Njoo FL, Beek WM, Keukens HJ, van Wilgenburg H, Oosting J, Stilma JS, et al. Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. American Journal of Tropical Medicine and Hygiene 1995;52(1):94-7.
42. Nájera JA, González-Silva M, Alonso PL. Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLOS Medicine 2011;8(1):e1000412.
43. Ouédraogo AL, Bastiaens GJ, Tiono AB, Guelbéogo WM, Kobylinski KC, Ouédraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clinical Infectious Diseases 2015;60(3):357-65.
44. Paaijmans KP, Thomas MB. The influence of mosquito resting behaviour and associated microclimate for malaria risk. Malaria Journal 2011;10:183.
45. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD008846.pub2]
46. Quiñones ML, Lines JD, Thomson MC, Jawara M, Morris J, Greenwood BM. Anopheles gambiae gonotrophic cycle duration, biting and exiting behaviour unaffected by permethrin-impregnated bednets in the Gambia. Medical and Veterinary Entomology 1997;11(1):71-8.
47. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
48. Riveron JM, Osae M, Egyir-Yawson A, Irving H, Ibrahim SS, Wondji CS. Multiple insecticide resistance in the major malaria vector Anopheles funestus in southern Ghana: implications for malaria control. Parasites & Vectors 2016;9(1):504. [PUBMED: 27628765]
49. Russell TL, Beebe NW, Cooper RD, Lobo NF, Burkot TR. Successful malaria elimination strategies require interventions that target changing vector behaviours. Malaria Journal 2013;12:56.
50. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007483.pub2]
51. Sougoufara S, Diédhiou SM, Doucouré S, Diagne N, Sembéne PM, Harry M, et al. Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: a new challenge to malaria elimination. Malaria Journal 2014;13:125.
52. Strode C, Donegan S, Garner P, Enayati AA, Hemingway J. The impact of pyrethroid resistance on the efficacy of insecticide-treated bed nets against African anopheline mosquitoes: systematic review and meta-analysis. PLOS Medicine 2014;11(3):e1001619.
53. Sy VE, Agnew P, Sidobre C, Michalakis Y. Reduced survival and reproductive success generates selection pressure for the dengue mosquito Aedes aegypti to evolve resistance against infection by the microsporidian parasite Vavraia culicis. Evolutionary Applications 2014;7(4):468-79.
54. Thomsen EK, Koimbu G, Pulford J, Jamea-Maiasa S, Ura Y, Keven JB, et al. Mosquito behavior change after distribution of bednets results in decreased protection against malaria exposure. Journal of Infectious Diseases 2017;215(5):790-7.
55. Toé KH, N'Falé S, Dabiré RK, Ranson H, Jones CM. The recent escalation in strength of pyrethroid resistance in Anopheles coluzzi in West Africa is linked to increased expression of multiple gene families. BMC Genomics 2015;16:146.
56. World Health Organization. World Malaria Report 2015. www.who.int/malaria/publications/world-malaria-report-2015/report/en/ (accessed 30 May 2018).
57. World Health Organization. Global technical strategy for malaria 2016-2030. http://apps.who.int/iris/bitstream/10665/176712/1/9789241564991_eng.pdf?ua=1&ua=1 (accessed 30 May 2018).
58. World Health Organization. WHO policy brief on single-dose primaquine as gametocytocide in Plasmodium falciparum malaria. January 2015. www.who.int/malaria/publications/atoz/who_htm_gmp_2015.1.pdf (accessed 30 May 2018).
59. World Health Organization. WHO preferred product characteristics: endectocide for malaria transmission control. http://apps.who.int/iris/bitstream/10665/255694/1/WHO-HTM-GMP-2017.10-eng.pdf?ua=1 (accessed 30 May 2018).
60. Wolstenholme AJ. Glutamate-gated chloride channels. Journal of Biological Chemistry 2012;287(48):40232-8.